Hims & Hers Health, Inc. is a consumer-first health and wellness platform that leverages technology to provide accessible and affordable healthcare solutions. The company offers a wide range of prescription and non-prescription products, telehealth services, and wellness content through its websites, mobile applications, and retail partnerships. Its offerings focus on addressing common health conditions, promoting lifelong wellness, and simplifying the healthcare experience for customers.
-
Online Revenue - Provides prescription and non-prescription products directly to individual customers through the company's websites and mobile applications. Includes telehealth consultations with licensed healthcare professionals who can prescribe medications when appropriate, fulfilled via licensed pharmacies.
- Prescription Products - Addresses conditions such as sexual health, hair loss, dermatology, mental health, weight loss, and primary care.
- Non-Prescription Products - Includes over-the-counter drugs, cosmetics, supplements, and wellness items such as melatonin, biotin, skincare products, sexual health products, and hair care solutions.
-
Wholesale Revenue - Sells products to wholesale partners and third-party platforms, making Hims & Hers products available in tens of thousands of retail locations across the United States.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Andrew Dudum ExecutiveBoard | CEO and Chairman | None | Co-founder of Hims, Inc. in 2016; serial entrepreneur and investor; previously co-founded Atomic Labs and other startups. Holds a B.A. in Management and Economics from Wharton. | View Report → |
Dr. Patrick Carroll Executive | Chief Medical Officer | Board Member at ChristianaCare | Rejoined Hims & Hers in December 2022; previously served as CMO for Vida Health and WHOOP. Former CMO of Walgreens. Holds a medical degree from Dartmouth Medical School. | |
Melissa Baird Executive | COO | None | Joined Hims & Hers in February 2018; previously held leadership roles at Draper James, Bonobos, and Zulily. Holds a B.S. in Biological Sciences from the University of Missouri. | |
Mike Chi Executive | Chief Commercial Officer | None | Joined Hims & Hers in April 2021; previously held leadership roles at Zola, INTERMIX, and Gilt Groupe. Brings over 20 years of experience in consumer internet. | |
Soleil Boughton Executive | Chief Legal Officer | Board Member at CaringBridge | Joined Hims & Hers in October 2018; previously in-house counsel at Google Cloud Healthcare and a partner at Jones Day. Holds a B.A. from Pomona College and a J.D. from UCLA. | |
Yemi Okupe Executive | CFO | None | Joined Hims & Hers in January 2022; previously held senior financial roles at Uber, Hipcamp, and PayPal. Holds an MBA from Stanford and is a CFA and CPA. | |
Andrea Perez Board | Director | Advisory roles for startups in services and technology sectors | Former SVP at Sony Interactive Entertainment and VP/GM at Nike. Co-founder of Women of Nike employee group. Holds a B.A. in Economics from Harvard. | |
Anja Manuel Board | Director | Board Member at Ripple Labs; Member of U.S. Defense Department Policy Board | Co-founder of Rice, Hadley, Gates & Manuel LLC; Executive Director of Aspen Strategy Group. Extensive experience in foreign policy and governance. | |
Christiane Pendarvis Board | Director | Co-CEO of PATTERN Beauty; Board Member at Hootsuite | Former Co-President of Savage X Fenty; extensive experience in DTC and retail operations. Holds a B.A. from Harvard and an MBA from UNC Kenan-Flagler. | |
Christopher Payne Board | Director | Board Member at Gogo Inc. | Former President and COO of DoorDash; previously held leadership roles at Tinder, eBay, Microsoft, and Amazon. Holds a B.S. in Commerce and English from the University of Virginia. | |
David Wells Board | Lead Independent Director | Board Member at The Trade Desk and Wise PLC | Former CFO of Netflix (2010-2019); extensive experience in financial planning and analysis. Holds a B.S. from the University of Virginia and an MBA from the University of Chicago. | |
Deb Autor Board | Director | None | Former FDA official; serves on Hims & Hers Risk Committee. Also provides consulting services to Hims & Hers. Holds extensive regulatory and compliance expertise. | |
Dr. Delos Cosgrove Board | Director | Board Member at American Well Corp. (Amwell) and View, Inc. | Former CEO of Cleveland Clinic (2004-2017); currently an Executive Advisor at Cleveland Clinic. Holds a medical degree and extensive experience in healthcare leadership. | |
Kåre Schultz Board | Director | None | Former CEO of Teva Pharmaceuticals; extensive experience in pharmaceutical and healthcare industries. Appointed to Hims & Hers board in July 2024. |
- Given the recent gross margin degradation driven by the scaling of your weight loss specialty, particularly GLP-1 offerings, how do you plan to offset these margin pressures going forward, and what are your expectations for gross margins as this segment continues to grow?
- With the evolving regulatory landscape around compounded GLP-1 medications and potential shortages of name-brand options, how do you anticipate these factors impacting your weight loss specialty, and what steps are you taking to mitigate associated risks?
- You mentioned significant investments in both 503(a) and 503(b) facilities to support personalized weight loss solutions; can you elaborate on how these investments align with your capital allocation priorities and their expected impact on operational efficiency?
- Considering that higher-priced weight loss solutions contribute to the increased average revenue per subscriber, how sustainable is this growth, and what strategies are you implementing to ensure long-term retention and diversification across other specialties?
- As you broaden your personalized and multi-specialty offerings, what challenges do you foresee in maintaining high retention rates and customer satisfaction, especially with the integration of new treatments like GLP-1s, and how do you plan to address them?
Research analysts who have asked questions during Hims & Hers Health earnings calls.
Daniel Grosslight
Citigroup
4 questions for HIMS
Eric Percher
Nephron Research
4 questions for HIMS
Maria Ripps
Morgan Stanley
4 questions for HIMS
Ryan MacDonald
Needham & Company
4 questions for HIMS
Aaron Kessler
Seaport Research Partners
3 questions for HIMS
Craig Hettenbach
Morgan Stanley
3 questions for HIMS
Jonna Kim
TD Cowen
3 questions for HIMS
David Larsen
BTIG
2 questions for HIMS
George Hill
Deutsche Bank
2 questions for HIMS
Allen Lutz
Bank of America
1 question for HIMS
Brian Tanquilut
Jefferies
1 question for HIMS
Jailendra Singh
Truist Securities
1 question for HIMS
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MedisourceRx (Seaview Enterprises LLC) | 2024 | The acquisition closed on September 5, 2024 for a total purchase price of $31.0 million structured as $15.5 million in cash and 976,341 shares of Class A common stock, and it enhanced Hims & Hers’ capabilities by acquiring a 503B compounding outsourcing facility with key allocations including $28.6 million for the pharmacy license and $1.8 million in goodwill, with post-closing adjustments within 90 days. |
Honest Health Limited (HHL) | 2021 | Acquired in June 2021 for $4.8 million (including earn-out components settled partly in 2024 via cash and stock-based compensation), the deal was aimed at broadening Hims & Hers’ presence in the UK through strategic health and wellness products, with ongoing stock compensation and earn-out adjustments finalized in 2024. |
YoDerm, Inc. (Apostrophe) | 2021 | Completed in July 2021 for a total purchase price of $131.6 million—a blend of $48.2 million in cash, 8,074,935 shares of Class A common stock, and contingent earn-out—this acquisition expanded Hims & Hers’ dermatology and personalized healthcare offerings by integrating Apostrophe’s compounding pharmacy operations and recognizing $2.7 million in goodwill. |
Recent press releases and 8-K filings for HIMS.
- Hims & Hers Health, Inc. (Hims) is facing a wrongful death lawsuit filed this week by the parents of Luke Tyler in King County Superior Court.
- The lawsuit alleges that Hims prescribed a 90-day supply of an antidepressant to Luke Tyler, who had a disclosed history of undiagnosed depression and self-harm, following an Instagram ad. The dosage was later doubled without consultation, and Luke subsequently died by suicide using the prescribed medication.
- The Tylers claim Luke's death was a foreseeable consequence of Hims' expansion into mental healthcare via telehealth, alleging the company used Affiliated Medical Groups (AMGs) with unqualified medical professionals to circumvent regulations and rapidly issue prescriptions, violating Washington law.
- Hims & Hers has launched Labs, a new service offering a proactive and accessible healthcare experience that includes blood tests, personalized health insights, and actionable treatment plans.
- Labs provides two options: a base option with 50 biomarker tests and an advanced option with over 120 biomarker tests across 10 key categories, measured twice a year.
- The platform leverages machine learning and AI to identify personalized treatment options and plans to expand into advanced diagnostics for chronic diseases, cancers, and genetic risk markers at a reduced cost.
- Hims & Hers has introduced Labs, a new proactive healthcare experience designed to provide accessible and actionable health insights through comprehensive testing and personalized recommendations.
- The Labs service allows users to get blood drawn for biomarker testing, receive a detailed health picture, and access treatment plans and lifestyle recommendations from independent providers via the Hims & Hers app.
- Labs offers a Base option with 50 biomarker tests and an Advanced option with over 120 biomarker tests performed twice yearly, leveraging AI and machine learning for personalized treatment identification.
- Hims & Hers plans future expansions for Labs to include in-home testing and advanced diagnostics for chronic diseases, various cancers, and genetic risk markers, which they intend to offer at a fraction of typical costs.
- Hims & Hers Health has launched Labs, a new product designed to provide personalized health insights derived from blood tests.
- Labs offers two subscription plans: a $199 base plan for one annual blood draw covering 50 biomarkers, and a $499 advanced plan with two draws analyzing over 120 biomarkers.
- The service aims to make proactive, data-driven healthcare more accessible and affordable and is part of Hims & Hers' strategy to stimulate growth amid challenges in its core sexual health and weight-loss businesses.
- The company acquired Trybe Labs, an at-home blood-testing facility, in February to support this initiative.
- Hims & Hers Health reported Q3 2025 revenue of approximately $599 million, representing 49% year-over-year growth and surpassing market expectations, although the company missed GAAP EPS estimates and provided Q4 revenue guidance slightly below analyst forecasts.
- The company narrowed its full-year 2025 adjusted EBITDA guidance to a range of roughly $307 million to $317 million.
- While maintaining a strong gross margin near 76% and growing its subscriber base to over 2.4 million customers, operating margins declined significantly to 2% in Q3 2025 from 5.6% in the prior year, and free cash flow margin also decreased.
- Hims & Hers Health reported Q3 2025 revenue of nearly $600 million, marking a 49% year-over-year increase, and achieved adjusted EBITDA of $78 million with over 13% margins.
- The company provided Q4 2025 revenue guidance of $605 million to $625 million and adjusted EBITDA guidance of $55 million to $65 million. For full-year 2025, revenue is projected to be between $2.335 billion and $2.355 billion, with adjusted EBITDA between $307 million and $317 million.
- Strategic developments include active discussions with Novo Nordisk to make Wegovy available, a partnership with Marius Pharmaceuticals for an FDA-approved oral testosterone treatment in 2026, and a strategic investment in GRAIL for multi-cancer early detection.
- New offerings include a perimenopause and menopause solution for the Hers brand, which is expected to reach $1 billion in annual revenue in 2026, and a planned launch of comprehensive whole-body lab testing before year-end.
- The company is expanding its operational footprint to over 1 million sq ft by year-end and continues international expansion, including the Zava acquisition in Europe and upcoming entry into Canada.
- Hims & Hers reported robust Q3 2025 financial performance, with revenue growing 49% year-over-year to nearly $600 million and adjusted EBITDA increasing over 50% year-over-year to $78 million.
- The company is expanding its product offerings and partnerships, including active discussions with Novo Nordisk for Wegovy access, a partnership with Marius Pharmaceuticals for an oral testosterone treatment in 2026, and a strategic investment in GRAIL for multi-cancer early detection.
- New specialties are being launched, such as a low testosterone offering in Q3 2025, perimenopause and menopause support in Q4 2025, and comprehensive lab testing diagnostics before year-end.
- The Hers brand is projected to achieve over $1 billion in annual revenue in 2026.
- International expansion is a key focus, with plans to launch in Canada soon and a long-term target of over $1 billion in potential annual revenue from international markets, leveraging the Zava Global acquisition.
- Hims & Hers reported Q3 2025 revenue of nearly $600 million, a 49% year-over-year increase, and adjusted EBITDA of $78 million, growing over 50% year-over-year, alongside a 20% year-over-year subscriber growth.
- The company updated its full-year 2025 revenue guidance to $2.335 billion-$2.355 billion and adjusted EBITDA guidance to $307 million-$317 million.
- Strategic initiatives include active discussions with Novo Nordisk for Wegovy, a partnership with Marius Pharmaceuticals for oral testosterone in 2026, and a strategic investment in GRAIL for multi-cancer early detection.
- Hims & Hers plans to launch comprehensive, whole-body lab testing before year-end, expects its Hers brand to reach $1 billion in annual revenue by 2026, and will launch a longevity specialty in 2026.
- The company is expanding internationally, with plans to launch in Canada soon and projects over $1 billion in potential annual revenue from international markets, while reaffirming its 2030 goals of over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
- Hims & Hers Health, Inc. reported strong Q3 2025 financial results, with revenue of nearly $600 million, marking a 49% year-over-year increase, alongside net income of nearly $16 million and Adjusted EBITDA exceeding $78 million.
- The company's subscriber base grew to almost 2.5 million, up 21% year-over-year in Q3 2025.
- Hims & Hers narrowed its full-year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million.
- The company is in active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy available through its platform.
- Hims & Hers is expanding its offerings by reducing prices for personalized GLP-1 treatment plans by up to 20% and launching new specialties in testosterone and menopause care, with plans for comprehensive lab testing and a longevity specialty in 2026.
- Hims & Hers Health has launched personalized telehealth treatment options for perimenopause and menopause, including hormone-replacement therapies, overseen by specialized licensed providers.
- This expansion is expected to drive the Hers division to surpass $1 billion in annual revenue by 2026, addressing a significant market of approximately 1.3 million U.S. women experiencing menopause each year. The company operates on a direct customer payment model and does not accept insurance.
- While the launch saw a positive investor response with shares rising over 2%, the company has recently faced challenges including a sequential sales decline, missed Wall Street revenue estimates, and executive turnover.